These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30063587)

  • 21. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens.
    Xu Q; Liu G; Yuan X; Xu M; Wang H; Ji J; Konda B; Black KL; Yu JS
    Stem Cells; 2009 Aug; 27(8):1734-40. PubMed ID: 19536809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
    Curran MA; Montalvo W; Yagita H; Allison JP
    Proc Natl Acad Sci U S A; 2010 Mar; 107(9):4275-80. PubMed ID: 20160101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting CD166
    El-Ashmawy NE; Salem ML; Abd El-Fattah EE; Khedr EG
    Toxicol Appl Pharmacol; 2021 Oct; 429():115699. PubMed ID: 34437932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
    Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma.
    Kos S; Lopes A; Preat V; Cemazar M; Lampreht Tratar U; Ucakar B; Vanvarenberg K; Sersa G; Vandermeulen G
    PLoS One; 2019; 14(5):e0217762. PubMed ID: 31150505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
    Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
    J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
    Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
    Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
    Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.
    Padrón Á; Hurez V; Gupta HB; Clark CA; Pandeswara SL; Yuan B; Svatek RS; Turk MJ; Drerup JM; Li R; Curiel TJ
    Exp Gerontol; 2018 May; 105():146-154. PubMed ID: 29326088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective tumor immunity to melanoma mediated by B16F10 cancer stem cell vaccine.
    Zhao F; Zhang R; Wang J; Wu D; Pan M; Li M; Guo M; Dou J
    Int Immunopharmacol; 2017 Nov; 52():238-244. PubMed ID: 28950176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes.
    Kursunel MA; Taskiran EZ; Tavukcuoglu E; Yanik H; Demirag F; Karaosmanoglu B; Ozbay FG; Uner A; Esendagli D; Kizilgoz D; Yilmaz U; Esendagli G
    Cancer Immunol Immunother; 2022 Feb; 71(2):445-459. PubMed ID: 34228218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
    Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18.
    Ma Z; Li W; Yoshiya S; Xu Y; Hata M; El-Darawish Y; Markova T; Yamanishi K; Yamanishi H; Tahara H; Tanaka Y; Okamura H
    Clin Cancer Res; 2016 Jun; 22(12):2969-80. PubMed ID: 26755531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
    Soares KC; Rucki AA; Wu AA; Olino K; Xiao Q; Chai Y; Wamwea A; Bigelow E; Lutz E; Liu L; Yao S; Anders RA; Laheru D; Wolfgang CL; Edil BH; Schulick RD; Jaffee EM; Zheng L
    J Immunother; 2015 Jan; 38(1):1-11. PubMed ID: 25415283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity.
    Yi H; Guo C; Yu X; Gao P; Qian J; Zuo D; Manjili MH; Fisher PB; Subjeck JR; Wang XY
    Cancer Res; 2011 Nov; 71(21):6611-20. PubMed ID: 21914786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.